Migraine Drugs Market
Migraine Drugs Market (Treatment - Abortive (Triptans and Ergot Alkoids) and Prophylactic (Botulinum Toxin and Topiramate); Route of Administration - Oral and Injectable; Distribution Channel - Retail Pharmacies and Hospital Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
Press Release :
The prevailing unhealthy food habits and hectic lifestyle of consumers across the world are the primary drivers of the global migraine drugs market. Further, the growing population and increasing awareness among consumers regarding the availability of the migraine treatment drugs are prominent factors fueling the growth in the global migraine drugs market. Furthermore, development of advanced drugs by the migraine drugs manufacturers is some other factor influencing growth in the market.
As per the Transparency Market Research, the global migraine drugs market reached a value of US$2.72 bn in 2016 and is expected to reach a value of US$3.72 bn by 2025. The global migraine drugs market is expected to register a steady CAGR 3.50% between 2017 and 2025. The market is mainly segmented into three segments namely Treatment, Route of Administration, and Distribution Channel.
Development of Advanced Migraine Drugs to Boost Growth of Migraine Drugs Market
From the perspective of treatment, the global migraine drugs market is divided into- Abortive, and Prophylactic segments. Further, Abortive segment is classified into triptans, alkoids, ergot and others based on the drug class. While prophylactic treatment is segmented into botulinum toxin, topiramate and others. Among these treatment segments, abortive procedure is likely to dominant market share in the global migraine drugs market whereas prophylactic treatment segment is projected to register a healthy growth during the forecast period that is from 2017 to 2025.
On the basis of route of administration segment, the global migraine drugs market is mainly segmented into oral, injectable and others. The other segment of route of administration includes nasal, spray, transdermal, patches and likewise. Among all of them, orally administrable drugs is likely to holds maximum potential for the global migraine market. And this is projected to continue in the upcoming years as well. This is mainly due to the low cost associated with the usage of oral drugs and vast availability of the oral drugs as compared to the other form across the globe. While on the basis of distribution channel the global migraine drugs market is segmented into hospital pharmacy and retail pharmacy.
North America Holds Immense Potential in Migraine Drugs Market
Based on Geography the global migraine drugs market segment is classified into five prime regions: North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. Among all these five region, North America is expected to account highest share in the global migraine drugs market during the upcoming years. This is mainly because of the increasing healthcare investment by the private and government bodies. Apart from this, increasing cases of migraine and easy avaiblity of the specialized migraine treatment are the some other headwinds propelling growth in the market. The region is anticipated to register a healthy 3.40% CAGR between 2017 and 2025.
The global migraine drug market depicts a fragmented competitive landscape owing to the presence of several players in the market. Some of the predominant players in the global migraine drugs market are Novartis AG, GlaxoSmithKline plc., Allergan Plc.,Avanir Pharmaceuticals, Inc., Janssen Pharmaceutical Company and ., Eisai Co.,
Migraine Drugs Market - Snapshot
The migraine drugs market features a fragmented and intensely competitive vendor landscape with the presence of several large players in the fray. To stay competitive, several large players are considering to launch revised version of their existing patent drugs and at the same launch new drugs. Besides this, large players in the migraine drugs market are striving for mergers and collaborations with regional players to consolidate their position in the global migraine drugs market.
North America is a prominent region in the global migraine drugs market. The presence of a well-established pharmaceutical industry in the region is a key factor for strong position of North America in the overall migraine drugs market. Moreover, high awareness for the risks of migraine, and the way it impacts quality of life accounts for substantial demand for migraine drugs in the region.
Meanwhile, the demand for migraine drugs is rising steadily in other key regions too. Firstly, the prevalence of migraine among individuals of all age groups that needs to be subsided with drugs fuels the migraine drugs market. Migraine is related to several factors, including food triggers, environment, hormones, or genetics. Nonetheless, so far, there has not been any line of treatment apart from prescription drugs to subside the pain. This creates massive opportunities in the migraine drugs market. In the coming years too, the migraine drugs market is anticipated to witness outstanding growth to be worth close to four billion dollars in the near future.
Key segments of the migraine drugs market based on treatment type are abortive and prophylactic. The abortive segment is further divided into alkoids, triptans, ergot, and others. On the other hand, prophylactic treatment segment is divided into topiramate, botulinum toxin, and others. The migraine drugs market is studied on the basis of route of administration as well. Oral, injectable, and others (transdermal, nasal spray, patches) are key segments of the migraine drugs market on the basis of route of administration.
Global Migraine Drugs Market: Scope and Methodology
This report on the global migraine drugs market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.
The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment and sub-segment for the period from 2017 to 2025, considering the macro and micro environmental factors. Growth rates for each segment within the global migraine drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.
A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global migraine drugs market.
Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year and 2015 as historic year. Market size estimations involved in-depth study of product features of different types of treatments & drug class and various pipeline products. Additionally, market related factors such as preference for self-medication, regional availability of specialty drugs, patent expiration of migraine drugs & availability of generic drugs, projected launch of new drugs etc. in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.
Migraine Drugs Market: Segmentation
Migraine is type of headache, estimated to affect 12 to 14.7% of population across the globe. According to international as well regional guidelines it is categorized by frequency and nature of attack into episodic migraine and chronic migraine. Abortive and prophylactic are the two treatments offered for migraine relief. Abortive treatment which is given to abort acute attack of migraine include medication such as triptans, ergot alkoids and others. While prophylactic treatment is recommended to patients with chronic migraine to prevent migraine attacks using medications such as botulinum toxin, topiramate and other drugs.
Based on treatment, the global migraine drugs market has been segmented into abortive and prophylactic. These treatments segments are further classified based on the drug class such as abortive treatment is classified into triptans, ergot alkoids, and others while prophylactic treatment is segmented into botulinum toxin, topiramate and others. Abortive treatment segment is projected to hold dominant share of global migraine drugs market while prophylactic treatment segment is likely to register steady growth during the forecast period from 2017 to 2025.
Based on route of administration, the global migraine drugs market is segmented into oral, injectable and others. Others segment of route of administration include nasal sprays, transdermal patches, etc. Low cost and vast availability of orally administrable drugs is projected to contribute for dominating share of oral segment of route of administration.
Based on the distribution channel, the global migraine drugs market is segmented into retail pharmacies, hospital pharmacies and others. Ever increasing number of retail pharmacies, self-medication with widely available OTC migraine abortive drugs is attributed for the significant share of the segment in the global market.
Migraine Drugs Market: Geographical and Competitive Dynamics
Geographically, the global migraine drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region.
The report also profiles major players in the migraine drugs market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include AstraZeneca Plc., Allergan Plc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc., Eli Lilly & Co. Novartis AG, Merck & Co., Inc., Valeant Pharmaceutical International, Inc., Janssen Pharmaceutical Company (Johnson & Johnson), Endo Pharmaceuticals Inc., Zosano Pharma Corporation, Alder BioPharmaceuticals Inc., and others.
The global migraine drugs market has been segmented as below:
by Route of Administration
by Distribution Channel